press center press release

Opexa Therapeutics Inc. (OPXA) CEO to Ring the NASDAQ Stock Market Closing Bell

Published

MEDIA ADVISORY, Sept. 15, 2006 (PRIMEZONE) --

What: David McWilliams, CEO of Opexa Therapeutics Inc. (OPXA) will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, September 18th, 2006 at 4:00 p.m. EDT Contacts: Lynne Hohlfeld lhohlfeld@opexatherapeutics.com NASDAQ MarketSite: Stephanie Lowenthal 646.441.5220

Feed Information:

The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Opexa Therapeutics Inc. (OPXA):

Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more